{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T04:41:52Z","timestamp":1791348112385,"version":"4.3.1"},"reference-count":45,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T00:00:00Z","timestamp":1696550400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.jfma.2023.10.004","type":"journal-article","created":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T19:00:09Z","timestamp":1697050809000},"page":"738-743","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Deciphering the diagnostic dilemma: A comprehensive review of the Taiwanese cardiac variant in Fabry disease"],"prefix":"10.1016","volume":"123","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6690-4879","authenticated-orcid":false,"given":"Wuh-Liang","family":"Hwu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5507","key":"10.1016\/j.jfma.2023.10.004_bib1","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1126\/science.1058040","article-title":"The sequence of the human genome","volume":"291","author":"Venter","year":"2001","journal-title":"Science"},{"issue":"6822","key":"10.1016\/j.jfma.2023.10.004_bib2","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/35057062","article-title":"Initial sequencing and analysis of the human genome","volume":"409","author":"Lander","year":"2001","journal-title":"Nature"},{"issue":"6588","key":"10.1016\/j.jfma.2023.10.004_bib3","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1126\/science.abj6987","article-title":"The complete sequence of a human genome","volume":"376","author":"Nurk","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.jfma.2023.10.004_bib4","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease","volume":"5","author":"Germain","year":"2010","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jfma.2023.10.004_bib5","series-title":"Fabry disease: perspectives from 5 Years of FOS","article-title":"The genetic basis of Fabry disease","author":"Gal","year":"2006"},{"issue":"5","key":"10.1016\/j.jfma.2023.10.004_bib6","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1136\/jmedgenet-2014-102797","article-title":"Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease","volume":"52","author":"Germain","year":"2015","journal-title":"J Med Genet"},{"issue":"1","key":"10.1016\/j.jfma.2023.10.004_bib7","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s40620-020-00721-4","article-title":"New drugs for the treatment of Anderson-Fabry disease","volume":"34","author":"Feriozzi","year":"2021","journal-title":"J Nephrol"},{"issue":"5","key":"10.1016\/j.jfma.2023.10.004_bib8","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1056\/NEJM199508033330504","article-title":"An atypical variant of Fabry\u2019s disease in men with left ventricular hypertrophy","volume":"333","author":"Nakao","year":"1995","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jfma.2023.10.004_bib9","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0002-9149(00)01275-3","article-title":"Molecular genetic, biochemical, and clinical studies in three families with cardiac Fabry\u2019s disease","volume":"87","author":"Yoshitama","year":"2001","journal-title":"Am J Cardiol"},{"issue":"4","key":"10.1016\/j.jfma.2023.10.004_bib10","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1086\/339431","article-title":"Alternative splicing in the alpha-galactosidase A gene: increased exon inclusion results in the Fabry cardiac phenotype","volume":"70","author":"Ishii","year":"2002","journal-title":"Am J Hum Genet"},{"issue":"1","key":"10.1016\/j.jfma.2023.10.004_bib11","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jjcc.2007.12.001","article-title":"Terminal stage cardiac findings in patients with cardiac Fabry disease: an electrocardiographic, echocardiographic, and autopsy study","volume":"51","author":"Takenaka","year":"2008","journal-title":"J Cardiol"},{"issue":"10","key":"10.1016\/j.jfma.2023.10.004_bib12","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1002\/humu.21074","article-title":"Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c.936+919G>A (IVS4+919G>A)","volume":"30","author":"Hwu","year":"2009","journal-title":"Hum Mutat"},{"issue":"1","key":"10.1016\/j.jfma.2023.10.004_bib13","doi-asserted-by":"crossref","first-page":"780","DOI":"10.2119\/molmed.2012.00002","article-title":"Fabry disease: incidence of the common later-onset\u00a0alpha-galactosidase A IVS4+919G-->A mutation in Taiwanese newborns\u2013superiority of DNA-based to enzyme-based newborn screening for common mutations","volume":"18","author":"Chien","year":"2012","journal-title":"Mol Med"},{"issue":"1","key":"10.1016\/j.jfma.2023.10.004_bib14","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ymgme.2010.08.023","article-title":"Elevation of urinary globotriaosylceramide (GL3) in infants with Fabry disease","volume":"102","author":"Chien","year":"2011","journal-title":"Mol Genet Metabol"},{"issue":"5","key":"10.1016\/j.jfma.2023.10.004_bib15","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s10545-012-9547-1","article-title":"Lyso-globotriaosylsphingosine (lyso-Gb3) levels in neonates and adults with the Fabry disease later-onset GLA IVS4+919G>A mutation","volume":"36","author":"Chien","year":"2013","journal-title":"J Inherit Metab Dis"},{"issue":"5","key":"10.1016\/j.jfma.2023.10.004_bib16","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1161\/CIRCGENETICS.109.862920","article-title":"High incidence of the cardiac variant of Fabry disease revealed by newborn screening in the Taiwan Chinese population","volume":"2","author":"Lin","year":"2009","journal-title":"Circ Cardiovasc Genet"},{"issue":"5","key":"10.1016\/j.jfma.2023.10.004_bib17","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s10545-010-9166-7","article-title":"Enzyme assay and clinical assessment in subjects with a Chinese hotspot late-onset Fabry mutation (IVS4 + 919G-->A)","volume":"33","author":"Lin","year":"2010","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.jfma.2023.10.004_bib18","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/1750-1172-9-96","article-title":"Endomyocardial biopsies in patients with left ventricular hypertrophy and a common Chinese later-onset Fabry mutation (IVS4 + 919G > A)","volume":"9","author":"Hsu","year":"2014","journal-title":"Orphanet J Rare Dis"},{"issue":"23","key":"10.1016\/j.jfma.2023.10.004_bib19","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1016\/j.jacc.2016.09.943","article-title":"Later onset fabry disease, cardiac damage progress in silence: experience with a highly prevalent mutation","volume":"68","author":"Hsu","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.jfma.2023.10.004_bib20","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18010119","article-title":"Correlations between endomyocardial biopsies and cardiac manifestations in Taiwanese patients with the Chinese hotspot IVS4+919G>A mutation: data from the fabry outcome survey","volume":"18","author":"Hsu","year":"2017","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.jfma.2023.10.004_bib21","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.3174\/ajnr.A4677","article-title":"Brain MR imaging findings of cardiac-type fabry disease with an IVS4+919G>A mutation","volume":"37","author":"Lee","year":"2016","journal-title":"AJNR Am J Neuroradiol"},{"issue":"7","key":"10.1016\/j.jfma.2023.10.004_bib22","first-page":"3","article-title":"Effects of enzyme replacement therapy for cardiac-type Fabry patients with a Chinese hotspot late-onset Fabry mutation (IVS4+919G>A)","author":"Lin","year":"2013","journal-title":"BMJ Open"},{"key":"10.1016\/j.jfma.2023.10.004_bib23","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13023-014-0111-y","article-title":"Globotriaosylsphingosine (lyso-Gb3) might not be a reliable marker for monitoring the long-term therapeutic outcomes of enzyme replacement therapy for late-onset Fabry patients with the Chinese hotspot mutation (IVS4+919G>A)","volume":"9","author":"Liu","year":"2014","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"10.1016\/j.jfma.2023.10.004_bib24","doi-asserted-by":"crossref","first-page":"126","DOI":"10.7150\/ijms.66448","article-title":"Fabry disease and the effectiveness of enzyme replacement therapy (ERT) in left ventricular hypertrophy (LVH) improvement: a review and meta-analysis","volume":"19","author":"Lee","year":"2022","journal-title":"Int J Med Sci"},{"issue":"1","key":"10.1016\/j.jfma.2023.10.004_bib25","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ymgme.2017.03.005","article-title":"Genetic epidemiological study doesn\u2019t support GLA IVS4+919G>A variant is a significant mutation in Fabry disease","volume":"121","author":"Chiang","year":"2017","journal-title":"Mol Genet Metabol"},{"issue":"5","key":"10.1016\/j.jfma.2023.10.004_bib26","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1159\/000494678","article-title":"Results of fabry disease screening in male pre-end stage renal disease patients with unknown etiology found through the platform of a chronic kidney disease education program in a northern taiwan medical center","volume":"43","author":"Lin","year":"2018","journal-title":"Kidney Blood Press Res"},{"issue":"3","key":"10.1016\/j.jfma.2023.10.004_bib27","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/ene.13775","article-title":"Genomic screening of Fabry disease in young stroke patients: the Taiwan experience and a review of the literature","volume":"26","author":"Lee","year":"2019","journal-title":"Eur J Neurol"},{"issue":"7","key":"10.1016\/j.jfma.2023.10.004_bib28","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/s10038-020-0745-7","article-title":"The Fabry disease-causing mutation, GLA IVS4+919G>A, originated in Mainland China more than 800 years ago","volume":"65","author":"Liang","year":"2020","journal-title":"J Hum Genet"},{"issue":"9","key":"10.1016\/j.jfma.2023.10.004_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0239675","article-title":"Screening for Fabry Disease in patients with unexplained left ventricular hypertrophy","volume":"15","author":"Sadasivan","year":"2020","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.jfma.2023.10.004_bib30","first-page":"10","article-title":"High prevalence of late-onset fabry cardiomyopathy in a cohort of 499 non-selective patients with left ventricular hypertrophy: the Asian fabry cardiomyopathy high-risk screening study (ASIAN-FAME)","author":"Fan","year":"2021","journal-title":"J Clin Med"},{"issue":"8","key":"10.1016\/j.jfma.2023.10.004_bib31","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/jhg.2013.48","article-title":"Newborn screening for Fabry disease in Japan: prevalence and genotypes of Fabry disease in a pilot study","volume":"58","author":"Inoue","year":"2013","journal-title":"J Hum Genet"},{"issue":"1","key":"10.1016\/j.jfma.2023.10.004_bib32","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.jjcc.2016.05.014","article-title":"Prevalence and clinical features of Fabry disease in Japanese male patients with diagnosis of hypertrophic cardiomyopathy","volume":"69","author":"Kubo","year":"2017","journal-title":"J Cardiol"},{"issue":"29","key":"10.1016\/j.jfma.2023.10.004_bib33","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000007387","article-title":"Clinical characteristics and mutation spectrum of GLA in Korean patients with Fabry disease by a nationwide survey: Underdiagnosis of late-onset phenotype","volume":"96","author":"Choi","year":"2017","journal-title":"Medicine"},{"issue":"8","key":"10.1016\/j.jfma.2023.10.004_bib34","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1073\/pnas.0712309105","article-title":"Elevated globotriaosylsphingosine is a hallmark of Fabry disease","volume":"105","author":"Aerts","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"10.1016\/j.jfma.2023.10.004_bib35","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s10157-017-1525-3","article-title":"Plasma lyso-Gb3: a biomarker for monitoring fabry patients during enzyme replacement therapy","volume":"22","author":"Sakuraba","year":"2018","journal-title":"Clin Exp Nephrol"},{"issue":"22","key":"10.1016\/j.jfma.2023.10.004_bib36","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1136\/heartjnl-2014-305616","article-title":"Familial globotriaosylceramide-associated cardiomyopathy mimicking Fabry disease","volume":"100","author":"Apelland","year":"2014","journal-title":"Heart"},{"issue":"3","key":"10.1016\/j.jfma.2023.10.004_bib37","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.kint.2018.02.003","article-title":"Hydroxychloroquine-induced mimic of renal Fabry disease","volume":"94","author":"Sperati","year":"2018","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.jfma.2023.10.004_bib38","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1515\/hsz-2019-0270","article-title":"Emerging mechanisms of drug-induced phospholipidosis","volume":"401","author":"Breiden","year":"2019","journal-title":"Biol Chem"},{"issue":"9","key":"10.1016\/j.jfma.2023.10.004_bib39","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1007\/s00467-020-04564-w","article-title":"Myelin bodies in LMX1B-associated nephropathy: potential for misdiagnosis","volume":"35","author":"Lei","year":"2020","journal-title":"Pediatr Nephrol"},{"issue":"14","key":"10.1016\/j.jfma.2023.10.004_bib40","first-page":"10","article-title":"Fabry cardiomyopathy: current treatment and future options","author":"Vardarli","year":"2021","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.jfma.2023.10.004_bib41","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1038\/s41598-018-19229-w","article-title":"Increased left ventricular mass index is present in patients with type 2 diabetes without ischemic heart disease","volume":"8","author":"Seferovic","year":"2018","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.jfma.2023.10.004_bib42","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s10741-019-09775-4","article-title":"Hypertrophic cardiomyopathy: an updated review on diagnosis, prognosis, and treatment","volume":"24","author":"Makavos","year":"2019","journal-title":"Heart Fail Rev"},{"issue":"1","key":"10.1016\/j.jfma.2023.10.004_bib43","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/cge.13027","article-title":"Hernandez Del Rincon JP, Gimeno JR. Genetics of hypertrophic cardiomyopathy: a review of current state","volume":"93","author":"Sabater-Molina","year":"2018","journal-title":"Clin Genet"},{"issue":"8","key":"10.1016\/j.jfma.2023.10.004_bib44","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1038\/s41436-019-0436-y","article-title":"Fabry disease cardiac variant IVS4+919 G>A is associated with multiple cardiac gene variants in patients with severe cardiomyopathy and fatal arrhythmia","volume":"21","author":"Juang","year":"2019","journal-title":"Genet Med"},{"issue":"1","key":"10.1016\/j.jfma.2023.10.004_bib45","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.113.000394","article-title":"Risk of death in heart disease is associated with elevated urinary globotriaosylceramide","volume":"3","author":"Schiffmann","year":"2014","journal-title":"J Am Heart Assoc"}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664623004023?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664623004023?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T19:31:29Z","timestamp":1719430289000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0929664623004023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":45,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S0929664623004023"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2023.10.004","relation":{},"ISSN":["0929-6646"],"issn-type":[{"value":"0929-6646","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Deciphering the diagnostic dilemma: A comprehensive review of the Taiwanese cardiac variant in Fabry disease","name":"articletitle","label":"Article Title"},{"value":"Journal of the Formosan Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfma.2023.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Formosan Medical Association. Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}